Tetraphase Pharmaceuticals, Inc. (TTPH)
(Delayed Data from NSDQ)
$1.06 USD
+0.07 (7.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.06 USD
+0.07 (7.07%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.
Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tetraphase (TTPH) delivered earnings and revenue surprises of 19.63% and -28.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.
Tetraphase Pharmaceuticals (TTPH) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tetraphase (TTPH) delivered earnings and revenue surprises of 4.31% and 115.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Tetraphase Pharmaceuticals (TTPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tetraphase (TTPH) delivered earnings and revenue surprises of -10.53% and -49.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Tetraphase Pharmaceuticals (TTPH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tetraphase (TTPH) delivered earnings and revenue surprises of 7.69% and -34.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tetraphase (TTPH) delivered earnings and revenue surprises of -5.71% and -44.93%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Tetraphase Pharmaceuticals (TTPH) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Tetraphase (TTPH) Stock
by Zacks Equity Research
Investors need to pay close attention to Tetraphase (TTPH) stock based on the movements in the options market lately.
Implied Volatility Surging for Tetraphase (TTPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tetraphase (TTPH) stock based on the movements in the options market lately.
Tetraphase Pharmaceuticals (TTPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tetraphase (TTPH) delivered earnings and revenue surprises of 50.00% and 418.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock
by Zacks Equity Research
Investors in Tetraphase Pharmaceuticals (TTPH) need to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock
by Zacks Equity Research
Tetraphase Pharmaceuticals (TTPH) needs Investors to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in Tetraphase Pharmaceuticals (TTPH) Stock?
by Zacks Equity Research
Investors in Tetraphase Pharmaceuticals (TTPH) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Tetraphase Pharmaceuticals (TTPH) Stock Options
by Zacks Equity Research
Investors in Tetraphase Pharmaceuticals, Inc. (TTPH) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Tetraphase Pharmaceuticals (TTPH) Stock Options
by Zacks Equity Research
Huge implied volatility makes Tetraphase Pharmaceuticals (TTPH) Stock lucrative to the option traders.
Are Options Traders Betting on a Big Move in Tetraphase (TTPH) Stock?
by Zacks Equity Research
Tetraphase (TTPH) Stock's substantial implied volatility might attract the option traders.